What Researchers Did
Researchers conducted a randomized, double-blind, sham-controlled trial with 61 post-stroke depression patients to see if hyperbaric oxygen therapy (HBOT) could reduce depression symptoms and increase brain-related growth factors.
What They Found
Patients receiving HBOT showed significantly lower depression scores (HAMD) compared to the sham group at both 2 weeks (p=0.017) and 4 weeks (p<0.01) after treatment. The HBOT group also had significantly higher levels of serum Brain-Derived Neurotrophic Factor (BDNF) and beta-Nerve Growth Factor (beta-NGF) (all p<0.01). These improvements in depression scores were linked to the increases in BDNF (r = 0.66, p < 0.05) and beta-NGF (r = 0.47, p =0.01).
What This Means for Canadian Patients
For Canadian patients who experience depression after a stroke, this study suggests that hyperbaric oxygen therapy could offer a new way to reduce their symptoms. The findings indicate that HBOT might work by increasing important brain growth factors, potentially leading to better recovery from post-stroke depression.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
The study involved a relatively small number of patients (61) and a short follow-up period of only four weeks, which may limit the generalizability of the findings.